Scientific journal Nature on Wednesday said a personalised treatment based on messenger RNA by BioNTech potentially bodes well for the future of fighting an extremely aggressive form of cancer after the regimen was shown to trigger a promising immune reaction in some pancreatic cancer patients.
FRANKFURT, May 10 - Scientific journal Nature on Wednesday said a personalised treatment based on messenger RNA by BioNTech
Results of a trial in the first phase of testing on humans showed that half of the 16 trial participants, who had undergone surgery to remove their tumour, had developed T cells that can potentially recognise cancerous cells and stop them from re-emerging, Nature said in a paper on Wednesday. "These data are exceedingly promising, and will provide the framework for a planned further clinical trial," the News & Views editorial segment of Nature said, citing the severity of the disease.Pancreatic cancer is among the most deadly forms of cancer because it typically grows undetected until an effective treatment is too late.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
‘Unjustly enriched:’ Core Scientific knocks back $4.7M claim from CelsiusDefunct Bitcoin miner Core Scientific has objected to a $4.7 million administrative claim from Celsius Network, claiming that the bankrupt crypto lender still owes roughly $11 million in unpaid power costs.
Weiterlesen »
Fake scientific papers are alarmingly commonBut new tools show promise in tackling growing symptom of academia’s “publish or perish” culture
Weiterlesen »
Medical and scientific experts advising FDA vote in favor of OTC birth control pillA group of external advisers to the US Food and Drug Administration voted in favor of an application from a pharmaceutical company to put their prescription birth control pill over the counter.
Weiterlesen »
Cash-rich BioNTech broadens scope as COVID shot sales slideGermany's BioNTech , Pfizer's partner on COVID-19 vaccines, said on Monday its first-quarter net income plunged on lower demand for the shots as it widens its work on cancer and other diseases.
Weiterlesen »
Higher rank chirality and non-Hermitian skin effect in a topolectrical circuit - Nature CommunicationsIn this work, the authors implement a crystalline rank-2 chiral modes by employing non-Hermitian dynamics. They showed the momentum-resolved dynamics and non-Hermitian skin effect associated with the rank-2 chirality both theoretically and experimentally.
Weiterlesen »
Fast and accurate protein structure search with Foldseek - Nature BiotechnologyFoldseek speeds up protein structural search by four to five orders of magnitude.
Weiterlesen »